drugset / Trial / NCT05743036
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
Phase 1
Terminated
44 enrolled
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Pfizer · collab
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
Timeline
- Start
- 2023-02-27
- Primary completion
- 2024-07-16
- Completion
- 2025-07-09
Outcome
Outcome not reported
Stopped: “Study terminated due to change in therapeutic landscape.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azenosertib | Small molecule | — | Oral |
| Subject | Cetuximab | Monoclonal antibody | — | Other |
| Subject | Encorafenib | Small molecule | — | Oral |